AstraZeneca PLC shed GBP15 billion of market capitalization on Tuesday, after investors were underwhelmed by early data from a trial of a weight-loss pill. The company (UK:AZN) said its lead product ...

Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

Promising data don’t always equal a stock pop. Viking Therapeutics presented what analysts thought were compelling data on an oral GLP-1/GIP dual agonist on Sunday ...

Viking Therapeutics reported clinical trial data on Sunday, which excited some investors. Despite signs that Viking's ...

Powerful weight-loss drugs like Wegovy and Zepbound have driven nearly $1 trillion in market-capitalization gains, with most ...

For high-profile biotech Viking Therapeutics (NASDAQ: VKTX), Monday was very much a good news/bad news kind of day. The ...

Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and ...

Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo ...

Viking (VKTX) stock fell 13% Monday afternoon after jumping 9% earlier in the day amid concerns the company might face production problems for its obesity drug candidate VK2735.

Constellation Energy stock is lower Monday as a regulatory decision offsets the utility company's solid third-quarter ...

Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...